2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2444 Romiplostim N01 versus recombinant human thrombopoietin for platelet engraftment after allogeneic transplantation in severe aplastic anemia: A real-world retrospective cohort study

Xianfu Sheng, MD, Linlin Huang Sr, MD2, Nanxi Dong, MD3, Yingying Shen4, Wenbin Liu, MD,PhD5, Baodong Ye, MD, PhD6, Yu Zhang Jr, MD7
1 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
2 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
3 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
4 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
5 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
6 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
7 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China

Delayed platelet engraftment remains a clinically important barrier after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for severe aplastic anemia (SAA), contributing to bleeding risk, transfusion dependence, infection vulnerability, and greater resource use. Recombinant human thrombopoietin (rhTPO) is used in China to promote post-transplant platelet recovery, but it requires daily injections and has limited availability outside China. Romiplostim N01 is a once-weekly thrombopoietin receptor agonist biosimilar approved in China for immune thrombocytopenia. We previously observed accelerated platelet recovery with Romiplostim N01 after autologous stem cell transplantation for plasma cell neoplasms. Its prophylactic role after allo-HSCT for SAA remains unclear.
We conducted a single-center retrospective cohort study of consecutive SAA patients undergoing first allo-HSCT between August 2024 and October 2025. This study was prospectively registered with the Chinese Clinical Trial Registry (ChiCTR2600128131). Patients received either prophylactic Romiplostim N01 (5 ug/kg subcutaneously once weekly from day +1, with escalation permitted to 10 ug/kg if platelet engraftment had not occurred by day +14) or rhTPO (300 U/kg/day subcutaneously from days +3 to +5). The primary endpoint was time to platelet engraftment. Secondary endpoints included time to neutrophil engraftment, cumulative incidence rates of both neutrophil and platelet engraftment at day +30, complete platelet recovery (≥100 x 109/L), transfusion burden, drug administration and cost, graft-versus-host disease (GVHD), infection, organ toxicity, overall survival (OS), and GVHD-free, failure-free survival (GFFS).
Fifty-four patients were included: 23 received Romiplostim N01 and 31 received rhTPO. Baseline patient, donor, conditioning, and graft characteristics were comparable between groups. Romiplostim N01 significantly shortened median platelet engraftment time compared with rhTPO (12 [range, 9-35] vs 15 [range, 11-96] days; P=0.007). The cumulative incidence of platelet engraftment at day +30 was higher in the Romiplostim N01 group than in the rhTPO group (95.7% vs 80.6%; P=0.003), as was complete platelet recovery (95.7% vs 71.0%; P=0.032). In multivariable analysis, Romiplostim N01 remained independently associated with day +30 platelet engraftment (OR, 2.185; 95% CI, 1.183-4.035; P=0.013). Neutrophil engraftment time was similar (11 vs 12 days; P=0.102), and no primary graft failure occurred. Secondary graft failure occurred in 0% versus 3.2% of patients (P=1.000). Platelet and red blood cell transfusion burden were not significantly different. However, Romiplostim N01 substantially reduced treatment burden, with fewer administrations per patient (median, 4 vs 17; P<0.001) and lower drug cost (5,900 vs 13,413 CNY; P<0.001).
Safety outcomes were comparable. The cumulative incidence of grade II-IV acute GVHD by day +100 was 26.1% versus 29.0% (P=0.663), and grade III-IV acute GVHD was 9.1% versus 16.1% (P=0.420). Two-year chronic GVHD was 15.1% versus 34.4% (P=0.154), and moderate-severe chronic GVHD was 10.3% versus 14.3% (P=0.812). EBV reactivation (82.6% vs 71.0%; P=0.322), EBV reactivation requiring rituximab (47.8% vs 35.5%; P=0.361), CMV reactivation (13.0% vs 12.9%; P=1.000), pneumonia, bacteremia, organ toxicity, hemorrhagic cystitis, and thrombotic microangiopathy did not differ significantly. No thromboembolic events or bone marrow fibrosis were observed.
With a median follow-up of 14 months in both groups, estimated 2-year OS was 78.1% versus 74.2% (P=0.385), and 2-year GFFS was 67.3% versus 52.7% (P=0.121). Romiplostim N01 was not independently associated with OS or GFFS in multivariable Cox models.
In this real-world cohort of SAA patients undergoing allo-HSCT, prophylactic once-weekly Romiplostim N01 was associated with faster platelet engraftment, higher day +30 platelet engraftment, and improved complete platelet recovery compared with daily rhTPO, without an apparent increase in GVHD, infectious complications, thrombosis, marrow fibrosis, or mortality. Romiplostim N01 may offer a convenient platelet-support strategy after allo-HSCT for SAA; prospective randomized studies are warranted.

Xianfu Sheng, MD: No relevant conflicts of interest to declare.